Arbutus Biopharma Corporation (ABUS)
ABUS moved a median of +0.11% 30 minutes after news, and +0.32% by the close. How ABUS actually reacts to news — the realized, point-in-time move the market made, measured across 191 labeled events over the last three years with zero look-ahead.
ABUS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 191 |
| 30-min | +0.11% | 52% | 191 |
| 60-min | +0.15% | 51% | 191 |
| to close | +0.32% | 52% | 188 |
| Middle 50% of ABUS reactions | -1.34% to +0.95% |
|---|---|
| Median reaction (30-min) | +0.11% |
| Measured reactions | 191 |
Half of all Arbutus Biopharma Corporation news events land between -1.34% and +0.95% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ABUS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ABUS's baseline. Nothing else.
Recent ABUS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer | Press release | GlobeNewswire | -1.15% | -4.40% | |
| Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer | Press release | GlobeNewswire | +2.78% | +2.14% | |
| Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share | Press release | GlobeNewswire | +1.35% | +0.39% | |
| Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer | Press release | GlobeNewswire | +2.88% | +0.19% | |
| Form 8-K Arbutus Biopharma Corp For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | +2.88% | +0.19% | |
| Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.20% | +0.00% | |
| Form 10-Q Arbutus Biopharma Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.20% | +0.00% | |
| Form 8-K Arbutus Biopharma Corp For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -2.20% | +0.00% | |
| Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders | Press release | GlobeNewswire | -1.90% | +0.00% | |
| Form 8-K Arbutus Biopharma Corp For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | -1.90% | +0.00% | |
| Form S-8 Arbutus Biopharma Corp | SEC filing · Form S-8 | SEC EDGAR | -0.23% | -0.94% | |
| Form 8-K Arbutus Biopharma Corp For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | -0.43% | |
| Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.45% | -4.01% | |
| Form 10-Q Arbutus Biopharma Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.45% | -4.01% | |
| Form 8-K Arbutus Biopharma Corp For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -1.45% | -4.01% | |
| Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B | Press release | GlobeNewswire | -0.44% | -1.75% | |
| Form 8-K Arbutus Biopharma Corp For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | -0.44% | -1.75% | |
| Form DEF 14A Arbutus Biopharma Corp For: May 26 | SEC filing · Form DEF | SEC EDGAR | -0.44% | -1.75% | |
| Form DEFA14A Arbutus Biopharma Corp | SEC filing · Form DEFA14A | SEC EDGAR | -0.44% | -1.75% | |
| Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +1.38% | |
| Form 10-K Arbutus Biopharma Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +1.38% | |
| Form 8-K Arbutus Biopharma Corp For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.38% | |
| Form 8-K Arbutus Biopharma Corp For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | +0.86% | +2.15% | |
| Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna | Press release | GlobeNewswire | +0.86% | +2.15% | |
| Form 8-K Arbutus Biopharma Corp For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +1.79% | +4.52% | |
| Form 8-K Arbutus Biopharma Corp For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -0.78% | +5.47% | |
| Form 8-K Arbutus Biopharma Corp For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | -4.94% | +2.79% | |
| Form 8-K Arbutus Biopharma Corp For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.86% | |
| Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.88% | — | |
| Form 10-Q Arbutus Biopharma Corp For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.88% | — | |
| Form 8-K Arbutus Biopharma Corp For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -1.88% | — | |
| Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 | Press release | GlobeNewswire | +1.15% | -1.15% | |
| Form 8-K Arbutus Biopharma Corp For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +1.15% | -1.15% | |
| Form 8-K Arbutus Biopharma Corp For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +2.48% | +4.05% | |
| Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.91% | +0.87% | |
| Form 10-Q Arbutus Biopharma Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.91% | +0.87% | |
| Form 8-K Arbutus Biopharma Corp For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -2.91% | +0.87% | |
| Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus | Press release | GlobeNewswire | +0.54% | -0.59% | |
| Form 8-K Arbutus Biopharma Corp For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | +0.54% | -0.59% | |
| Form 8-K Arbutus Biopharma Corp For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | +6.48% | |
| Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +0.32% | |
| Form 10-Q Arbutus Biopharma Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.43% | -0.32% | |
| Form 8-K Arbutus Biopharma Corp For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.32% | |
| Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 | Press release | GlobeNewswire | -1.77% | -2.95% | |
| Form 8-K Arbutus Biopharma Corp For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.77% | -2.95% | |
| Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 | Press release | GlobeNewswire | +0.31% | -0.92% | |
| Form 8-K Arbutus Biopharma Corp For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | -0.92% | |
| Form DEF 14A Arbutus Biopharma Corp For: May 21 | SEC filing · Form DEF | SEC EDGAR | -4.14% | -4.30% | |
| Form DEFA14A Arbutus Biopharma Corp | SEC filing · Form DEFA14A | SEC EDGAR | -4.14% | -4.30% | |
| Form 8-K Arbutus Biopharma Corp For: Mar 28 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | -5.28% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ABUS section they belong to.
Where else ABUS is measured.
ABUS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kezar Life Sciences, Inc. (KZR) | 192 | +0.14% | 55% |
| TAKEDA PHARMA (TKPYY) | 192 | 0.00% | 47% |
| BeiGene, Ltd. - American Depositary Shares (BGNE) | 191 | +0.11% | 52% |
| CYTODYN INC (CYDY) | 191 | -0.07% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Arbutus Biopharma Corporation's median reaction calculated?
Every labeled ABUS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 191 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of ABUS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ABUS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.